Results 171 to 180 of about 18,251 (231)
Some of the next articles are maybe not open access.
Bone, 2020
Alendronate was synthesized in 1970s in a search for inhibitors of calcification. Istituto Gentili investigators identified it as a potent inhibitor of bone resorption and obtained a patent covering its use in the treatment of osteoporosis and other disorders of excessive bone resorption in the 1980s.
Steven R. Cummings +3 more
openaire +2 more sources
Alendronate was synthesized in 1970s in a search for inhibitors of calcification. Istituto Gentili investigators identified it as a potent inhibitor of bone resorption and obtained a patent covering its use in the treatment of osteoporosis and other disorders of excessive bone resorption in the 1980s.
Steven R. Cummings +3 more
openaire +2 more sources
Pharmacokinetics of Alendronate
Clinical Pharmacokinetics, 1999Alendronate (alendronic acid; 4-amino-1-hydroxybutylidene bisphosphonate) has demonstrated effectiveness orally in the treatment and prevention of postmenopausal osteoporosis, corticosteroid-induced osteoporosis and Paget's disease of the bone. Its primary mechanism of action involves the inhibition of osteoclastic bone resorption. The pharmacokinetics
A G, Porras, S D, Holland, B J, Gertz
openaire +2 more sources
Treatments in Endocrinology, 2005
Alendronate/colecalciferol 70 mg/2800 IU, a once-weekly tablet containing the bisphosphonate alendronate and colecalciferol (the precursor of the biologically active form of vitamin D), has been approved for the treatment of osteoporosis in women and for increasing bone mass in men with osteoporosis.
Neil A, Reynolds, Monique P, Curran
openaire +2 more sources
Alendronate/colecalciferol 70 mg/2800 IU, a once-weekly tablet containing the bisphosphonate alendronate and colecalciferol (the precursor of the biologically active form of vitamin D), has been approved for the treatment of osteoporosis in women and for increasing bone mass in men with osteoporosis.
Neil A, Reynolds, Monique P, Curran
openaire +2 more sources
2013
This chapter is a review on physical and chemical properties, methods of preparation, analysis, as well as pharmacodynamics and pharmacokinetics of Alendronate sodium (4-amino-1-hydroxybutane-1,1-diphosphonic acid sodium salt), a bone metabolism regulator, indicated for the treatment of excessive bone resorption and osteoporosis.
Gennady, Ananchenko +2 more
openaire +2 more sources
This chapter is a review on physical and chemical properties, methods of preparation, analysis, as well as pharmacodynamics and pharmacokinetics of Alendronate sodium (4-amino-1-hydroxybutane-1,1-diphosphonic acid sodium salt), a bone metabolism regulator, indicated for the treatment of excessive bone resorption and osteoporosis.
Gennady, Ananchenko +2 more
openaire +2 more sources
JCR: Journal of Clinical Rheumatology, 1997
Alendronate is an aminobisphosphonate that was approved recently for the treatment of osteoporosis. Studies in ovariectomized rats and baboons have demonstrated the efficacy of this drug in animal models of osteoporosis. Alendronate prevented bone loss and increased bone mass and bone strength, relative to estrogen-deficient controls. Histomorphometric
openaire +3 more sources
Alendronate is an aminobisphosphonate that was approved recently for the treatment of osteoporosis. Studies in ovariectomized rats and baboons have demonstrated the efficacy of this drug in animal models of osteoporosis. Alendronate prevented bone loss and increased bone mass and bone strength, relative to estrogen-deficient controls. Histomorphometric
openaire +3 more sources
Drugs, 2001
Alendronate (alendronic acid) is a nitrogen-containing bisphosphonate which binds to bone surfaces and inhibits bone resorption by osteoclasts. Oral alendronate 5 or 10 mg/day produces sustained increases in bone mineral density (BMD) in postmenopausal women with or without osteoporosis, in men with primary osteoporosis and in both men and women with ...
M, Sharpe, S, Noble, C M, Spencer
openaire +2 more sources
Alendronate (alendronic acid) is a nitrogen-containing bisphosphonate which binds to bone surfaces and inhibits bone resorption by osteoclasts. Oral alendronate 5 or 10 mg/day produces sustained increases in bone mineral density (BMD) in postmenopausal women with or without osteoporosis, in men with primary osteoporosis and in both men and women with ...
M, Sharpe, S, Noble, C M, Spencer
openaire +2 more sources
On the Absorption of Alendronate in Rats
Journal of Pharmaceutical Sciences, 1994Alendronate is an antiosteolytic agent under investigation for the treatment of a number of bone disorders. Since the compound is a zwitterion with five pKa values and is completely ionized in the intestine at the physiological pH, absorption is poor; less than 1% of an oral dose is available systemically in rats. In the present studies, absorption was
J H, Lin, I W, Chen, F A, deLuna
openaire +2 more sources
Alendronate and Atrial Fibrillation
New England Journal of Medicine, 2007To the Editor: In this issue of the Journal, Black et al.1 report on a significant increase in the risk of serious atrial-fibrillation adverse events (defined as events resulting in hospitalization or disability or judged to be life-threatening) associated with once-yearly infusions of intravenous zoledronic acid for the treatment of osteoporosis in ...
Steven R, Cummings +2 more
openaire +2 more sources
Minerva Endocrinologica, 2020
Several formulations of vitamin D and alendronate are available for the treatment of osteoporosis. The objective of this study was to examine efficacy and safety of calcifediol (25(OH)D) compared to cholecalciferol (vitamin D3) and also the relationship between different formulations of alendronate and adverse reactions.We observed a population of ...
Emiliano, Giampà +8 more
openaire +2 more sources
Several formulations of vitamin D and alendronate are available for the treatment of osteoporosis. The objective of this study was to examine efficacy and safety of calcifediol (25(OH)D) compared to cholecalciferol (vitamin D3) and also the relationship between different formulations of alendronate and adverse reactions.We observed a population of ...
Emiliano, Giampà +8 more
openaire +2 more sources
Pharmacokinetics of Intrvenous Alendronate
The Journal of Clinical Pharmacology, 1999Alendronate is a potent bisphosphonate that has been studied for the treatment of osteoporosis and Paget's disease of the bone. To examine the pharmacokinetics of this drug, several groups of postmenopausal women were dosed intravenously in several studies.
V, Cocquyt +10 more
openaire +2 more sources